RGTLF Financials: Argent Biopharma Ltd AI Analysis

Home

Stock

RGTLF

Financials

RGTLF Financial

Argent Biopharma Ltd

$0.03

-47.82%

$-0.02

As of today:Mar 25, 14:56:22 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$0.0575

Open

$0.03

Day's Range

$0.03 - $0.03

52 week range

$0.0105 - $0.2092

Volume

Avg.Volume

3.1K

Dividend yield

EPS (TTM)

-0.22

Market Cap

$2.6M

What is Argent BioPharma Limited?

Argent BioPharma Ltd. engages in the production of medical marijuana. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. The Company’s assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The Company’s proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection. The company focuses on urgent unmet needs in the central nervous system (CNS) and systemic inflammation. Its product pipeline includes CimetrA, CannEpil, CogniCann and others. CannEpil is a refractory epilepsy seizure control treatment. CogniCann is an investigational oral spray developed by the Company to help manage symptoms associated with dementia and Alzheimer’s disease. The firm has a patient base in Australia, the United Kingdom, Brazil, and Ireland.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

RGTLF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	06/30/2025	06/30/2024	06/30/2023	06/30/2022	06/30/2021
Revenue	0	0	0	3	4	2
Revenue Growth (YoY)	--	--	-100%	-25%	100%	0%
Cost of Revenue	0	1	4	6	3	1
Gross Profit	0	-1	-3	-3	1	1
Selling, General & Admin	6	10	10	8	11	7
Research & Development	3	3	2	2	2	3
Operating Expenses	9	14	14	12	16	12
Other Non Operating Income (Expenses)	1	0	0	0	--	--
Pretax Income	-8	-17	-17	-21	-20	-15
Income Tax Expense	0	0	--	0	0	0
Net Income	-8	-17	-17	-20	-20	-15
Net Income Growth	-64%	0%	-15%	0%	33%	-21%
Shares Outstanding (Diluted)	76.24	57.17	37.01	2.93	2.56	1.9
Shares Change (YoY)	50%	54%	1,162%	14%	35%	-100%
EPS (Diluted)	-0.12	-0.31	-0.47	-7.1	-7.92	-8.32
EPS Growth	-71%	-34%	-93%	-10%	-5%	61,119%
Free Cash Flow	--	-9	-14	--	-14	-15
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	0%	0%	0%	-100%	25%	50%
Operating Margin	0%	0%	0%	-500%	-350%	-550%
Profit Margin	0%	0%	0%	-666.66%	-500%	-750%
Free Cash Flow Margin	--	0%	0%	--	-350%	-750%
EBITDA	--	-15	-17	-15	-14	-11
EBITDA Margin	--	0%	0%	-500%	-350%	-550%
D&A For EBITDA	--	0	1	0	0	0
EBIT	-9	-15	-18	-15	-14	-11
EBIT Margin	0%	0%	0%	-500%	-350%	-550%
Effective Tax Rate	0%	0%	--	0%	0%	0%

Follow-Up Questions

What are Argent Biopharma Ltd's key financial statements?



According to the latest financial statement (Form-10K), Argent Biopharma Ltd has a total asset of $2, Net loss of $-17

What are the key financial ratios for RGTLF?



Argent Biopharma Ltd's Current ratio is 0.18, has a Net margin is 0, sales per share of $0.

How is Argent Biopharma Ltd's revenue broken down by segment or geography?



Argent Biopharma Ltd largest revenue segment is Pharma, at a revenue of 804,832 in the most earnings release.For geography, Slovenia and Others is the primary market for Argent Biopharma Ltd, at a revenue of 440,443.

Is Argent Biopharma Ltd profitable?



no, according to the latest financial statements, Argent Biopharma Ltd has a net loss of $-17

Does Argent Biopharma Ltd have any liabilities?



yes, Argent Biopharma Ltd has liability of 11

How many outstanding shares for Argent Biopharma Ltd?



Argent Biopharma Ltd has a total outstanding shares of 72.18

Argent Biopharma Ltd (RGTLF) Financial

RGTLF Stock Price Chart